A comprehensive view of Lonza Group Ltd. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Chemicals Industry Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

RBC: Forecasting Lonza to average 10%-11% revenue growth per year, as almost half of its revenues come from biologics, which is expected to grow faster than overall market, and 10% from cells and gene therapy, which could grow in the high teens

Lonza completes early phase clinical manufacturing facility at small molecules plant in Bend, Oregon; facility has 11 suites, including seven GMP processing suites to manufacture spray-dried dispersion drug product intermediates and drug products

Lonza expands Capsugel capsule offering with new TiO2-free white hard gelatin capsule, meeting new TiO2-free requirements for foods in the EU; product features novel technology to give opaqueness and whiteness similar to that of TiO2

Lonza to divest site in Quakertown, Pennsylvania, to a group of investors and industry specialists; site specializes in particle size reduction, serving pharmaceutical and biotechnology end markets

Merck KGaA's MilliporeSigma acquires Lonza’s MAST platform, an automated aseptic bioreactor sampling system to advance bioprocessing; platform offers real-time data to cut process development time by half, lower biopharmaceutical manufacturing costs

Ask us about our Chemicals Industry market view

Trending Chart

Interactive chart with headline count